A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM

References

• Mercer B. Antibiotics in the management of PROM and preterm labor. Obstet Gynecol Clin North Am 2012;39:65–76
   PubMed Web of Science ®Google Scholar
• Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2013;12:CD001058
   PubMed Web of Science ®Google Scholar
• Parry S, Strauss J III. Premature rupture of the fetal membranes. N Engl J Med 1998;338:663–70
   PubMed Web of Science ®Google Scholar
• Romero R, Yeo L, Gotsch F, et al. Prelabor rupture of the membranes. In: Winn H, Chervanak F, Romero R, eds. Clinical maternal-fetal medicine online, 2nd ed. London (UK): Informa Healthcare; 2011:1–24
   Google Scholar
• Santolaya-Forgas J, Romero R, Espinoza J, et al. Prelabour rupture of the membranes. In: Reece E, Hobbins J, eds. Clinical obstetrics the fetus & mothers, 3rd ed. Malden (MA): Blackwell; 2008:1130–88
   Google Scholar
• Goldenberg R, Culhane J, Iams J, et al. Epidemiology and causes of preterm birth. Lancet 2008;371:75–84
   PubMed Web of Science ®Google Scholar
• Lebherz T, Hellman L, Madding R, et al. Double-blind study of premature rupture of the membranes: a report of 1,896 cases. Am J Obstet Gynecol 1963;87:218–25
   PubMed Web of Science ®Google Scholar
• Sacks M, Baker TH. Spontaneous premature rupture of the membranes: a prospective study. Am J Obstet Gynecol 1967;97:888–93
   PubMed Web of Science ®Google Scholar
• Gunn G, Mishell D Jr, Morton DG. Premature rupture of the fetal membranes: a review. Am J Obstet Gynecol 1970;106:469–83
   PubMed Web of Science ®Google Scholar
• Premature rupture of the membranes. Br Med J 1979;1:1165–6
   Google Scholar
• Gibbs R, Blanco JD. Premature rupture of the membranes. Obstet Gynecol 1982;60:671–9
   PubMed Web of Science ®Google Scholar
• Ismail A, Lahiri S. Management of prelabour rupture of membranes (PROM) at term. J Perinat Med 2013;41:647–9
   PubMed Web of Science ®Google Scholar
• Practice bulletins No. 139: premature rupture of membranes. Obstet Gynecol 2013;122:918–30
   Google Scholar
• Eschenbach D. Reply to: Ismail AQT, Lahiri S. Management of prelabor rupture of membranes (PROM) at term. J Perinat Med 2013;41:653–5
   PubMed Web of Science ®Google Scholar
• Grunebaum A. Reply to “Management of prelabour rupture of membranes (PROM) at term”. J Perinat Med 2013;41:651–2
   PubMed Web of Science ®Google Scholar
• Ramsauer B, Vidaeff A, Hosli I, et al. The diagnosis of rupture of fetal membranes (ROM): a meta-analysis. J Perinat Med 2013;41:233–40
   PubMed Web of Science ®Google Scholar
• Gelber S, Brent E, Varrey A, et al. Equivalence of erythromycin and azithromycin for treatment of PPROM (abstract 690). Am J Obstet Gynecol 2013;208:S291
   Web of Science ®Google Scholar
• Pintucci A, Meregalli V, Colombo P, et al. Premature rupture of membranes at term in low risk women: how long should we wait in the “latent phase”? J Perinat Med 2014;42:189–96
   PubMed Web of Science ®Google Scholar
• Wong L, Holmgren C, Silver R, et al. Outcomes of expectantly managed pregnancies with multiple gestations and preterm premature rupture of membranes prior to 26 weeks. Am J Obstet Gynecol 2015;212:215 e1–9
   PubMed Web of Science ®Google Scholar
• Manuck T, Varner MW. Neonatal and early childhood outcomes following early vs later preterm premature rupture of membranes. Am J Obstet Gynecol 2014;211:308 e1–6
   PubMed Web of Science ®Google Scholar
• Mehari K, Kneitel A, Langen E. Antibiotic administration in periviable premature rupture of membrane (abstract 532). Am J Obstet Gynecol 2014;210:S262
   PubMed Web of Science ®Google Scholar
• Lee J, Kang M, Kim E, et al. Effect of triple antibiotics on amniotic fluid infection/inflammation: an inter-era comparison of 20 years in patients with preterm PROM (abstract 475). Am J Obstet Gynecol (Supplement) 2014;210:S238
   Web of Science ®Google Scholar
• Saccone G, Berghella V. Antibiotic prophylaxis for term or near-term premature rupture of membranes: metaanalysis of randomized trials. Am J Obstet Gynecol 2014 Dec 30. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kacerovsky M, Musilova I, Hornychova H, et al. Bedside assessment of amniotic fluid interleukin-6 in preterm prelabor rupture of membranes. Am J Obstet Gynecol 2014;211:385 e1–9
   PubMed Web of Science ®Google Scholar
• Wong L, Holmgren C, Silver R, et al. Outcomes of expectantly managed pregnancies with multiple gestations and preterm premature rupture of membranes prior to 26 weeks. Am J Obstet Gynecol 2015;212:215 e211–19
   Google Scholar
• Romero R, Espinoza J, Kusanovic J, et al. The preterm parturition syndrome. BJOG 2006;113:17–42
   PubMed Web of Science ®Google Scholar
• Romero R. Prenatal medicine: the child is the father of the man. 1996. J Matern Fetal Neonatal Med 2009;22:636–9
   PubMed Web of Science ®Google Scholar
• Di Renzo GC. The great obstetrical syndromes. J Matern Fetal Neonatal Med 2009;22:633–5
   PubMed Web of Science ®Google Scholar
• Romero R, Lockwood CJ. Pathogenesis of spontaneous preterm labor. In: Creasy R, Resnik R, Iams J, eds. Creasy and Resnik's maternal-fetal medicine: principles and practice. Philadelphia (PA): Elsevier; 2009:521–43
   Google Scholar
• Romero R, Dey S, Fisher SJ. Preterm labor: one syndrome, many causes. Science 2014;345:760–5
   PubMed Web of Science ®Google Scholar
• Garite T, Freeman RK. Chorioamnionitis in the preterm gestation. Obstet Gynecol 1982;59:539–45
   PubMed Web of Science ®Google Scholar
• Cotton D, Hill L, Strassner H, et al. Use of amniocentesis in preterm gestation with ruptured membranes. Obstet Gynecol 1984;63:38–43
   PubMed Web of Science ®Google Scholar
• Zlatnik F, Cruikshank D, Petzold C, et al. Amniocentesis in the identification of inapparent infection in preterm patients with premature rupture of the membranes. J Reprod Med 1984;29:656–60
   PubMed Web of Science ®Google Scholar
• Broekhuizen F, Gilman M, Hamilton PR. Amniocentesis for gram stain and culture in preterm premature rupture of the membranes. Obstet Gynecol 1985;66:316–21
   PubMed Web of Science ®Google Scholar
• Feinstein S, Vintzileos A, Lodeiro J, et al. Amniocentesis with premature rupture of membranes. Obstet Gynecol 1986;68:147–52
   PubMed Web of Science ®Google Scholar
• Romero R, Quintero R, Oyarzun E, et al. Intraamniotic infection and the onset of labor in preterm premature rupture of the membranes. Am J Obstet Gynecol 1988;159:661–6
   PubMed Web of Science ®Google Scholar
• Dudley J, Malcolm G, Ellwood D. Amniocentesis in the management of preterm premature rupture of the membranes. Aust NZ J Obstet Gynaecol 1991;31:331–6
   PubMed Web of Science ®Google Scholar
• Romero R, Yoon B, Mazor M, et al. A comparative study of the diagnostic performance of amniotic fluid glucose, white blood cell count, interleukin-6, and gram stain in the detection of microbial invasion in patients with preterm premature rupture of membranes. Am J Obstet Gynecol 1993;169:839–51
   PubMed Web of Science ®Google Scholar
• Font G, Gauthier D, Meyer W, et al. Catalase activity as a predictor of amniotic fluid culture results in preterm labor or premature rupture of membranes. Obstet Gynecol 1995;85:656–8
   PubMed Web of Science ®Google Scholar
• Yoon B, Jun J, Park K, et al. Serum C-reactive protein, white blood cell count, and amniotic fluid white blood cell count in women with preterm premature rupture of membranes. Obstet Gynecol 1996;88:1034–40
   PubMed Web of Science ®Google Scholar
• Blackwell S, Berry SM. Role of amniocentesis for the diagnosis of subclinical intra-amniotic infection in preterm premature rupture of the membranes. Curr Opin Obstet Gynecol 1999;11:541–7
   PubMed Web of Science ®Google Scholar
• Romero R, Espinoza J, Chaiworapongsa T, et al. Infection and prematurity and the role of preventive strategies. Semin Neonatol 2002;7:259–74
   PubMedGoogle Scholar
• Shim S, Romero R, Hong J, et al. Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. Am J Obstet Gynecol 2004;191:1339–45
   PubMed Web of Science ®Google Scholar
• Romero R, Espinoza J, Goncalves L, et al. The role of inflammation and infection in preterm birth. Semin Reprod Med 2007;25:21–39
   PubMed Web of Science ®Google Scholar
• Oh K, Lee K, Sohn Y, et al. Intraamniotic infection with genital mycoplasmas exhibits a more intense inflammatory response than intraamniotic infection with other microorganisms in patients with preterm premature rupture of membranes. Am J Obstet Gynecol 2010;203:211 e211–18
   Web of Science ®Google Scholar
• Lee S, Romero R, Lee S, et al. Amniotic fluid volume in intra-amniotic inflammation with and without culture-proven amniotic fluid infection in preterm premature rupture of membranes. J Perinat Med 2010;38:39–44
   PubMed Web of Science ®Google Scholar
• Cobo T, Palacio M, Martinez-Terron M, et al. Clinical and inflammatory markers in amniotic fluid as predictors of adverse outcomes in preterm premature rupture of membranes. Am J Obstet Gynecol 2011;205:126 e121–8
   Web of Science ®Google Scholar
• Kacerovsky M, Musilova I, Khatibi A, et al. Intraamniotic inflammatory response to bacteria: analysis of multiple amniotic fluid proteins in women with preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med 2012;25:2014–19
   PubMed Web of Science ®Google Scholar
• Kacerovsky M, Andrys C, Hornychova H, et al. Amniotic fluid soluble Toll-like receptor 4 in pregnancies complicated by preterm prelabor rupture of the membranes. J Matern Fetal Neonatal Med 2012;25:1148–55
   PubMed Web of Science ®Google Scholar
• Agrawal V, Hirsch E. Intrauterine infection and preterm labor. Semin Fetal Neonatal Med 2012;17:12–19
   PubMed Web of Science ®Google Scholar
• Kacerovsky M, Andrys C, Drahosova M, et al. Soluble toll-like receptor 1 family members in the amniotic fluid of women with preterm prelabor rupture of the membranes. J Matern Fetal Neonatal Med 2012;25:1699–704
   PubMed Web of Science ®Google Scholar
• Kacerovsky M, Cobo T, Andrys C, et al. The fetal inflammatory response in subgroups of women with preterm prelabor rupture of the membranes. J Matern Fetal Neonatal Med 2013;26:795–801
   PubMed Web of Science ®Google Scholar
• Romero R, Chaemsaithong P, Korzeniewski S, et al. A point of care test for interleukin-6 in amniotic fluid in preterm prelabor rupture of membranes: a step toward the early treatment of acute intra-amniotic inflammation/infection. J Maternal Fetal Neonatal Med 2014 (submitted)
   Google Scholar
• Combs C, Gravett M, Garite T, et al. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. Am J Obstet Gynecol 2014;210:125 e121–5 e115
   Web of Science ®Google Scholar
• DiGiulio D, Romero R, Kusanovic J, et al. Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. Am J Reprod Immunol 2010;64:38–57
   PubMed Web of Science ®Google Scholar
• Kacerovsky M, Pliskova L, Bolehovska R, et al. The microbial load with genital mycoplasmas correlates with the degree of histologic chorioamnionitis in preterm PROM. Am J Obstet Gynecol 2011;205:213 e211–17
   Web of Science ®Google Scholar
• Romero R, Miranda J, Chaemsaithong P, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med 2014 Sep 29. [Epub ahead of print]. doi:10.3109/14767058.2014.958463
   Web of Science ®Google Scholar
• Kacerovsky M, Menon R, Drahosova M, et al. Amniotic fluid nucleosome in pregnancies complicated by preterm prelabor rupture of the membranes. J Matern Fetal Neonatal Med 2014;27:155–61
   PubMed Web of Science ®Google Scholar
• Fortner K, Grotegut C, Ransom C, et al. Bacteria localization and chorion thinning among preterm premature rupture of membranes. PLoS One 2014;9:e83338
   PubMed Web of Science ®Google Scholar
• Kacerovsky M, Musilova I, Andrys C, et al. Prelabor rupture of membranes between 34 and 37 weeks: the intraamniotic inflammatory response and neonatal outcomes. Am J Obstet Gynecol 2014;210:325 e321–5 e310
   Web of Science ®Google Scholar
• Kim K, Romero R, Park H, et al. A rapid matrix metalloproteinase-8 bedside test for the detection of intraamniotic inflammation in women with preterm premature rupture of membranes. Am J Obstet Gynecol 2007;197:292 e291–5
   Web of Science ®Google Scholar
• Tsiartas P, Kacerovsky M, Musilova I, et al. The association between histological chorioamnionitis, funisitis and neonatal outcome in women with preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med 2013;26:1332–6
   PubMed Web of Science ®Google Scholar
• Bastek J, Weber A, McShea M, et al. Prenatal inflammation is associated with adverse neonatal outcomes. Am J Obstet Gynecol 2014;210:450.e1–10
   PubMed Web of Science ®Google Scholar
• Armstrong-Wells J, Donnelly M, Post M, et al. Inflammatory predictors of neurologic disability after preterm premature rupture of membranes. Am J Obstet Gynecol 2015;212:212 e1--9
   PubMed Web of Science ®Google Scholar
• Simhan H, Canavan TP. Preterm premature rupture of membranes: diagnosis, evaluation and management strategies. BJOG 2005;112:32–7
   PubMed Web of Science ®Google Scholar
• van der Ham D, Nijhuis J, Mol B, et al. Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial). BMC Pregn Childbirth 2007;7:11
   PubMedGoogle Scholar
• Manuck T, Maclean C, Silver R, et al. Preterm premature rupture of membranes: does the duration of latency influence perinatal outcomes? Am J Obstet Gynecol 2009;201:414 e411–16
   Google Scholar
• Waters T, Mercer BM. The management of preterm premature rupture of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009;201:230–40
   PubMed Web of Science ®Google Scholar
• Singh K, Mercer B. Antibiotics after preterm premature rupture of the membranes. Clin Obstet Gynecol 2011;54:344–50
   PubMed Web of Science ®Google Scholar
• Faksh A, Wax J, Lucas F, et al. Preterm premature rupture of membranes ≥ 32 weeks' gestation: impact of revised practice guidelines. Am J Obstet Gynecol 2011;205:340 e341–5
   Google Scholar
• Melamed N, Ben-Haroush A, Pardo J, et al. Expectant management of preterm premature rupture of membranes: is it all about gestational age? Am J Obstet Gynecol 2011;204:48 e41–8
   Google Scholar
• Nold C, Hussain N, Smith K, et al. Optimal time for delivery with preterm premature rupture of membranes from 32 to 36 6/7 weeks. J Matern Fetal Neonatal Med 2011;24:933–5
   PubMed Web of Science ®Google Scholar
• Di Renzo G, Roura L, Facchinetti F, et al. Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern Fetal Neonatal Med 2011;24:659–67
   PubMed Web of Science ®Google Scholar
• Grigsby P, Novy M, Sadowsky D, et al. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am J Obstet Gynecol 2012;207:475 e471–5 e414
   Google Scholar
• van der Ham D, van der Heyden J, Opmeer B, et al. Management of late-preterm premature rupture of membranes: the PPROMEXIL-2 trial. Am J Obstet Gynecol 2012;207:276.e1–10
   Web of Science ®Google Scholar
• Rutanen EM. Comment on: guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes and preventive tools for preterm birth. J Matern Fetal Neonatal Med 2012;25:546–9 (author reply 547–8)
   PubMed Web of Science ®Google Scholar
• Mousiolis A, Papantoniou N, Mesogitis S, et al. Optimum mode of delivery in gestations complicated by preterm premature rupture of the membranes. J Matern Fetal Neonatal Med 2012;25:1044–9
   PubMed Web of Science ®Google Scholar
• Canzoneri B, Grotegut C, Swamy G, et al. Maternal serum interleukin-6 levels predict impending funisitis in preterm premature rupture of membranes after completion of antibiotics. J Matern Fetal Neonatal Med 2012;25:1329–32
   PubMed Web of Science ®Google Scholar
• Hunter T, Byrnes M, Nathan E, et al. Factors influencing survival in pre-viable preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2012;25:1755–61
   PubMed Web of Science ®Google Scholar
• Dagklis T, Petousis S, Margioula-Siarkou C, et al. Parameters affecting latency period in PPROM cases: a 10-year experience of a single institution. J Matern Fetal Neonatal Med 2013;26:1455–8
   PubMed Web of Science ®Google Scholar
• Dudenhausen JW. Primary prevention of preterm birth. J Perinat Med 2014;42:431–3
   PubMed Web of Science ®Google Scholar
• Amon E, Lewis S, Sibai B, et al. Ampicillin prophylaxis in preterm premature rupture of the membranes: a prospective randomized study. Am J Obstet Gynecol 1988;159:539–43
   PubMed Web of Science ®Google Scholar
• Johnston M, Sanchez-Ramos L, Vaughn A, et al. Antibiotic therapy in preterm premature rupture of membranes: a randomized, prospective, double-blind trial. Am J Obstet Gynecol 1990;163:743–7
   PubMed Web of Science ®Google Scholar
• McGregor J, French J, Seo K. Antimicrobial therapy in preterm premature rupture of membranes: results of a prospective, double-blind, placebo-controlled trial of erythromycin. Am J Obstet Gynecol 1991;165:632–40
   PubMed Web of Science ®Google Scholar
• Christmas J, Cox S, Andrews W, et al. Expectant management of preterm ruptured membranes: effects of antimicrobial therapy. Obstet Gynecol 1992;80:759–62
   PubMed Web of Science ®Google Scholar
• Kurki T, Hallman M, Zilliacus R, et al. Premature rupture of the membranes: effect of penicillin prophylaxis and long-term outcome of the children. Am J Perinatol 1992;9:11–16
   PubMed Web of Science ®Google Scholar
• Mercer B, Moretti M, Prevost R, et al. Erythromycin therapy in preterm premature rupture of the membranes: a prospective, randomized trial of 220 patients. Am J Obstet Gynecol 1992;166:794–802
   PubMed Web of Science ®Google Scholar
• Lockwood C, Costigan K, Ghidini A, et al. Double-blind: placebo-controlled trial of piperacillin prophylaxis in preterm membrane rupture. Am J Obstet Gynecol 1993;169:970–6
   PubMed Web of Science ®Google Scholar
• Owen J, Groome L, Hauth JC. Randomized trial of prophylactic antibiotic therapy after preterm amnion rupture. Am J Obstet Gynecol 1993;169:976–81
   PubMed Web of Science ®Google Scholar
• Ernest J, Givner LB. A prospective, randomized, placebo-controlled trial of penicillin in preterm premature rupture of membranes. Am J Obstet Gynecol 1994;170:516–21
   PubMed Web of Science ®Google Scholar
• Grable I, Garcia P, Perry D, et al. Group B Streptococcus and preterm premature rupture of membranes: a randomized, double-blind clinical trial of antepartum ampicillin. Am J Obstet Gynecol 1996;175:1036–42
   PubMed Web of Science ®Google Scholar
• Mercer B, Miodovnik M, Thurnau G, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997;278:989–95
   PubMed Web of Science ®Google Scholar
• Magwali T, Chipato T, Majoko F, et al. Prophylactic augmentin in prelabor preterm rupture of the membranes. Int J Gynaecol Obstet 1999;65:261–5
   PubMed Web of Science ®Google Scholar
• Kenyon S, Taylor D, Tarnow-Mordi W. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group. Lancet 2001;357:979–88
   PubMed Web of Science ®Google Scholar
• Lewis D, Adair C, Robichaux A, et al. Antibiotic therapy in preterm premature rupture of membranes: are seven days necessary? A preliminary, randomized clinical trial. Am J Obstet Gynecol 2003;188:1413–6 (discussion 1416–17)
   PubMed Web of Science ®Google Scholar
• Kwak H, Shin M, Cha H, et al. The efficacy of cefazolin plus macrolide (erythromycin or clarithromycin) versus cefazolin alone in neonatal morbidity and placental inflammation for women with preterm premature rupture of membranes. Placenta 2013;34:346–52
   PubMed Web of Science ®Google Scholar
• August Fuhr N, Becker C, van Baalen A, et al. Antibiotic therapy for preterm premature rupture of membranes – results of a multicenter study. J Perinat Med 2006;34:203–6
   PubMed Web of Science ®Google Scholar
• Hutzal C, Boyle E, Kenyon S, et al. Use of antibiotics for the treatment of preterm parturition and prevention of neonatal morbidity: a metaanalysis. Am J Obstet Gynecol 2008;199:620 e621–8
   Google Scholar
• Lamont RF. Antibiotics used in women at risk of preterm birth. Am J Obstet Gynecol 2008;199:583–4
   PubMed Web of Science ®Google Scholar
• Ehsanipoor R, Chung J, Clock C, et al. A retrospective review of ampicillin-sulbactam and amoxicillin + clavulanate vs cefazolin/cephalexin and erythromycin in the setting of preterm premature rupture of membranes: maternal and neonatal outcomes. Am J Obstet Gynecol 2008;198:e54–6
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin No. 80. Premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2007;109:1007–19
   PubMedGoogle Scholar
• Kenyon S, Pike K, Jones D, et al. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. Lancet 2008;372:1310–18
   PubMed Web of Science ®Google Scholar
• Philipson A, Sabath L, Charles D. Transplacental passage of erythromycin and clindamycin. N Engl J Med 1973;288:1219–21
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Laine K, Neuvonen P, et al. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG 2000;107:770–5
   PubMed Web of Science ®Google Scholar
• Ramsey P, Vaules M, Vasdev G, et al. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol 2003;188:714–18
   PubMed Web of Science ®Google Scholar
• Witt A, Sommer E, Cichna M, et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol 2003;188:816–19
   PubMed Web of Science ®Google Scholar
• Park H, Ahn B, Kwan Jun J. Placental transfer of clarithromycin in human pregnancies with preterm premature rupture of membranes. J Perinat Med 2012;40:641--6
   PubMed Web of Science ®Google Scholar
• Freeman C, Klutman N, Lamp KC. Metronidazole. A therapeutic review and update. Drugs 1997;54:679–708
   PubMed Web of Science ®Google Scholar
• Brook I, Wexler H, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 2013;26:526–46
   PubMed Web of Science ®Google Scholar
• Novak A, Rubic Z, Dogas V, et al. Antimicrobial susceptibility of clinically isolated anaerobic bacteria in a University Hospital Center Split, Croatia in 2013. Anaerobe 2015;31:31--6
   PubMed Web of Science ®Google Scholar
• Sobel JD. Bacterial vaginosis – an ecologic mystery. Ann Intern Med 1989;111:551–3
   PubMed Web of Science ®Google Scholar
• Sobel JD. Bacterial vaginosis. Br J Clin Pract Suppl 1990;71:65–9
   PubMedGoogle Scholar
• Cook R, Redondo-Lopez V, Schmitt C, et al. Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol 1992;30:870–7
   PubMed Web of Science ®Google Scholar
• Joesoef M, Schmid G, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999;28:S57–65
   Web of Science ®Google Scholar
• Sobel JD. Bacterial vaginosis. Ann Rev Med 2000;51:349–56
   PubMed Web of Science ®Google Scholar
• Donders G, Vereecken A, Bosmans E, et al. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG 2002;109:34–43
   PubMed Web of Science ®Google Scholar
• Haggerty C, Hillier S, Bass D, et al. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis 2004;39:990–5
   PubMed Web of Science ®Google Scholar
• Ferris M, Masztal A, Aldridge K, et al. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 2004;4:5
   PubMed Web of Science ®Google Scholar
• Romero R, Chaiworapongsa T, Kuivaniemi H, et al. Bacterial vaginosis, the inflammatory response and the risk of preterm birth: a role for genetic epidemiology in the prevention of preterm birth. Am J Obstet Gynecol 2004;190:1509–19
   PubMed Web of Science ®Google Scholar
• Hillier SL. The complexity of microbial diversity in bacterial vaginosis. N Engl J Med 2005;353:1886–7
   PubMed Web of Science ®Google Scholar
• Lamont R, Taylor-Robinson D. Review of the accuracy of various diagnostic tests for bacterial vaginosis to predict preterm birth (Honest et al., BJOG, May 2004). BJOG 2005;112:259–60 (author reply 260–1)
   PubMedGoogle Scholar
• Fredricks D, Fiedler T, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005;353:1899–911
   PubMed Web of Science ®Google Scholar
• Austin M, Meyn L, Hillier SL. Susceptibility of vaginal bacteria to metronidazole and tinidazole. Anaerobe 2006;12:227–30
   PubMed Web of Science ®Google Scholar
• Donders GG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol 2007;21:355–73
   PubMed Web of Science ®Google Scholar
• Brotman R, Ravel J. Ready or not: the molecular diagnosis of bacterial vaginosis. Clin Infect Dis 2008;47:44–6
   PubMed Web of Science ®Google Scholar
• Verstraelen H, Verhelst R. Bacterial vaginosis: an update on diagnosis and treatment. Expert Rev Anti Infect Ther 2009;7:1109–24
   PubMed Web of Science ®Google Scholar
• Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet Gynecol Surv 2010;65:462–73
   PubMed Web of Science ®Google Scholar
• Lamont R, Taylor-Robinson D. The role of bacterial vaginosis, aerobic vaginitis, abnormal vaginal flora and the risk of preterm birth. BJOG 2010;117:119–20 (author reply 120–1)
   PubMed Web of Science ®Google Scholar
• Zhou X, Brotman R, Gajer P, et al. Recent advances in understanding the microbiology of the female reproductive tract and the causes of premature birth. Infect Dis Obstet Gynecol 2010;2010:737425
   PubMedGoogle Scholar
• Marrazzo J, Martin D, Watts D, et al. Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis 2010;37:732–44
   PubMed Web of Science ®Google Scholar
• Lamont R, Sobel J, Akins R, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 2011;118:533–49
   PubMed Web of Science ®Google Scholar
• Turovskiy Y, Sutyak Noll K, Chikindas ML. The aetiology of bacterial vaginosis. J Appl Microbiol 2011;110:1105–28
   PubMed Web of Science ®Google Scholar
• Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA 2011;108:4680–7
   PubMed Web of Science ®Google Scholar
• Donders GG. The prevalence of bacterial vaginosis and aerobic vaginitis in young Finish women. APMIS 2011;119:224–5 (author reply 226)
   PubMed Web of Science ®Google Scholar
• Ma B, Forney L, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol 2012;66:371–89
   PubMed Web of Science ®Google Scholar
• Brocklehurst P, Gordon A, Heatley E, et al. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2013;1:CD000262
   PubMed Web of Science ®Google Scholar
• Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol 2013;209:505–23
   PubMed Web of Science ®Google Scholar
• Donders G, Zodzika J, Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother 2014;15:645–57
   PubMed Web of Science ®Google Scholar
• Fredricks D, Fiedler T, Thomas K, et al. Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol 2014;52:3137
   Web of Science ®Google Scholar
• Gomez L, Sammel M, Appleby D, et al. Evidence of a gene-environment interaction that predisposes to spontaneous preterm birth: a role for asymptomatic bacterial vaginosis and DNA variants in genes that control the inflammatory response. Am J Obstet Gynecol 2010;202:386 e381–6
   Google Scholar
• Mancuso M, Figueroa D, Szychowski J, et al. Midtrimester bacterial vaginosis and cervical length in women at risk for preterm birth. Am J Obstet Gynecol 2011;204:342 e341–5
   Google Scholar
• Foxman B, Wen A, Srinivasan U, et al. Mycoplasma, bacterial vaginosis-associated bacteria BVAB3, race, and risk of preterm birth in a high-risk cohort. Am J Obstet Gynecol 2014;210:226 e221–7
   Google Scholar
• Adu A, Armour CL. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Drugs 1995;50:423–39
   PubMed Web of Science ®Google Scholar
• Klein N, Cunha BA. Third-generation cephalosporins. Med Clin North Am 1995;79:705–19
   PubMed Web of Science ®Google Scholar
• Lamb H, Ormrod D, Scott L, et al. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs 2002;62:1041–89
   PubMed Web of Science ®Google Scholar
• Kechagia N, Bersimis S, Chatzipanagiotou S. Incidence and antimicrobial susceptibilities of genital mycoplasmas in outpatient women with clinical vaginitis in Athens, Greece. J Antimicrob Chemother 2008;62:122–5
   PubMed Web of Science ®Google Scholar
• Dongya M, Wencheng X, Xiaobo M, et al. Transition mutations in 23S rRNA account for acquired resistance to macrolides in Ureaplasma urealyticum. Microb Drug Resist 2008;14:183–6
   PubMed Web of Science ®Google Scholar
• Bayraktar M, Ozerol I, Gucluer N, et al. Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women. Int J Infect Dis 2010;14:e90–5
   PubMed Web of Science ®Google Scholar
• Xiao L, Crabb D, Duffy L, et al. Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in human Ureaplasma spp. Int J Antimicrob Agents 2011;37:377–9
   PubMed Web of Science ®Google Scholar
• Redelinghuys M, Ehlers M, Dreyer A, et al. Antimicrobial susceptibility patterns of Ureaplasma species and Mycoplasma hominis in pregnant women. BMC Infect Dis 2014;14:171
   PubMed Web of Science ®Google Scholar
• Gomez R, Romero R, Nien J, et al. Antibiotic administration to patients with preterm premature rupture of membranes does not eradicate intra-amniotic infection. J Matern Fetal Neonatal Med 2007;20:167–73
   PubMed Web of Science ®Google Scholar
• Yoon B, Romero R, Lim J, et al. The clinical significance of detecting Ureaplasma urealyticum by the polymerase chain reaction in the amniotic fluid of patients with preterm labor. Am J Obstet Gynecol 2003;189:919–24
   PubMed Web of Science ®Google Scholar
• Yoon B, Yang S, Jun J, et al. Maternal blood C-reactive protein, white blood cell count, and temperature in preterm labor: a comparison with amniotic fluid white blood cell count. Obstet Gynecol 1996;87:231–7
   PubMed Web of Science ®Google Scholar
• Lee J, Oh K, Yang H, et al. The importance of intra-amniotic inflammation in the subsequent development of atypical chronic lung disease. J Matern Fetal Neonatal Med 2009;22:917–23
   PubMed Web of Science ®Google Scholar
• Maymon E, Romero R, Pacora P, et al. Human neutrophil collagenase (matrix metalloproteinase 8) in parturition, premature rupture of the membranes, and intrauterine infection. Am J Obstet Gynecol 2000;183:94–9
   PubMed Web of Science ®Google Scholar
• Park J, Romero R, Yoon B, et al. The relationship between amniotic fluid matrix metalloproteinase-8 and funisitis. Am J Obstet Gynecol 2001;185:1156–61
   PubMed Web of Science ®Google Scholar
• Yoon B, Oh S, Romero R, et al. An elevated amniotic fluid matrix metalloproteinase-8 level at the time of mid-trimester genetic amniocentesis is a risk factor for spontaneous preterm delivery. Am J Obstet Gynecol 2001;185:1162–7
   PubMed Web of Science ®Google Scholar
• Moon J, Kim J, Yoon B, et al. Amniotic fluid matrix metalloproteinase-8 and the development of cerebral palsy. J Perinat Med 2002;30:301–6
   PubMed Web of Science ®Google Scholar
• Nien J, Yoon B, Espinoza J, et al. A rapid MMP-8 bedside test for the detection of intra-amniotic inflammation identifies patients at risk for imminent preterm delivery. Am J Obstet Gynecol 2006;195:1025–30
   PubMed Web of Science ®Google Scholar
• Park C, Yoon B, Kim S, et al. The frequency and clinical significance of intra-amniotic inflammation defined as an elevated amniotic fluid matrix metalloproteinase-8 in patients with preterm labor and low amniotic fluid white blood cell counts. Obstet Gynecol Sci 2013;56:167–75
   PubMedGoogle Scholar
• Kim S, Romero R, Park J, et al. The relationship between the intensity of intra-amniotic inflammation and the presence and severity of acute histologic chorioamnionitis in preterm gestation. J Matern Fetal Neonatal Med 2014 Oct 20. [Epub ahead of print]. doi:10.3109/14767058.2014.961009
   Web of Science ®Google Scholar
• Yoon B, Romero R, Kim C, et al. Amniotic fluid interleukin-6: a sensitive test for antenatal diagnosis of acute inflammatory lesions of preterm placenta and prediction of perinatal morbidity. Am J Obstet Gynecol 1995;172:960–70
   PubMed Web of Science ®Google Scholar
• Redline R, Heller D, Keating S, et al. Placental diagnostic criteria and clinical correlation – a workshop report. Placenta 2005;26:S114–17
   PubMed Web of Science ®Google Scholar
• Redline RW. Inflammatory responses in the placenta and umbilical cord. Semin Fetal Neonatal Med 2006;11:296–301
   PubMed Web of Science ®Google Scholar
• Yoon B, Romero R, Park J, et al. The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. Am J Obstet Gynecol 2000;183:1124–9
   PubMed Web of Science ®Google Scholar
• Pacora P, Chaiworapongsa T, Maymon E, et al. Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. J Matern Fetal Neonatal Med 2002;11:18–25
   PubMedGoogle Scholar
• Yoon B, Romero R, Shim J, et al. C-reactive protein in umbilical cord blood: a simple and widely available clinical method to assess the risk of amniotic fluid infection and funisitis. J Matern Fetal Neonatal Med 2003;14:85–90
   PubMedGoogle Scholar
• Lee J, Oh K, Park C, et al. The presence of funisitis is associated with a decreased risk for the development of neonatal respiratory distress syndrome. Placenta 2011;32:235–40
   PubMed Web of Science ®Google Scholar
• Yoon B, Jun J, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997;177:19–26
   PubMed Web of Science ®Google Scholar
• Yoon B, Romero R, Park J, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol 2000;182:675–81
   PubMed Web of Science ®Google Scholar
• Cassell G, Davis R, Waites K, et al. Isolation of Mycoplasma hominis and Ureaplasma urealyticum from amniotic fluid at 16–20 weeks of gestation: potential effect on outcome of pregnancy. Sex Transm Dis 1983;10:294–302
   PubMed Web of Science ®Google Scholar
• Gauthier D, Meyer W, Bieniarz A. Correlation of amniotic fluid glucose concentration and intraamniotic infection in patients with preterm labor or premature rupture of membranes. Am J Obstet Gynecol 1991;165:1105–10
   PubMed Web of Science ®Google Scholar
• Romero R, Mazor M, Morrotti R, et al. Infection and labor: VII. Microbial invasion of the amniotic cavity in spontaneous rupture of membranes at term. Am J Obstet Gynecol 1992;166:129–33
   PubMed Web of Science ®Google Scholar
• Gray D, Robinson H, Malone J, et al. Adverse outcome in pregnancy following amniotic fluid isolation of Ureaplasma urealyticum. Prenat Diagn 1992;12:111–17
   PubMed Web of Science ®Google Scholar
• Horowitz S, Mazor M, Romero R, et al. Infection of the amniotic cavity with Ureaplasma urealyticum in the midtrimester of pregnancy. J Reprod Med 1995;40:375–9
   PubMed Web of Science ®Google Scholar
• Yoon B, Romero R, Park J, et al. Microbial invasion of the amniotic cavity with Ureaplasma urealyticum is associated with a robust host response in fetal, amniotic, and maternal compartments. Am J Obstet Gynecol 1998;179:1254–60
   PubMed Web of Science ®Google Scholar
• Yoon B, Romero R, Kim M, et al. Clinical implications of detection of Ureaplasma urealyticum in the amniotic cavity with the polymerase chain reaction. Am J Obstet Gynecol 2000;183:1130–7
   PubMed Web of Science ®Google Scholar
• Perni S, Vardhana S, Korneeva I, et al. Mycoplasma hominis and Ureaplasma urealyticum in midtrimester amniotic fluid: association with amniotic fluid cytokine levels and pregnancy outcome. Am J Obstet Gynecol 2004;191:1382–6
   PubMed Web of Science ®Google Scholar
• Olomu I, Hecht J, Onderdonk A, et al. Perinatal correlates of Ureaplasma urealyticum in placenta parenchyma of singleton pregnancies that end before 28 weeks of gestation. Pediatrics 2009;123:1329–36
   PubMed Web of Science ®Google Scholar
• Jacobsson B, Aaltonen R, Rantakokko-Jalava K, et al. Quantification of Ureaplasma urealyticum DNA in the amniotic fluid from patients in PTL and pPROM and its relation to inflammatory cytokine levels. Acta Obstet Gynecol Scand 2009;88:63–70
   PubMed Web of Science ®Google Scholar
• Jacobsson B, Mattsby-Baltzer I, Andersch B, et al. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women with preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand 2003;82:423–31
   PubMed Web of Science ®Google Scholar
• Kacerovsky M, Pavlovsky M, Tosner J. Preterm premature rupture of the membranes and genital mycoplasmas. Acta Medica (Hradec Kralove) 2009;52:117–20
   PubMedGoogle Scholar
• Capoccia R, Greub G, Baud D. Ureaplasma urealyticum, Mycoplasma hominis and adverse pregnancy outcomes. Curr Opin Infect Dis 2013;26:231–40
   PubMed Web of Science ®Google Scholar
• Kwak D, Hwang H, Kwon J, et al. Co-infection with vaginal Ureaplasma urealyticum and Mycoplasma hominis increases adverse pregnancy outcomes in patients with preterm labor or preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2014;27:333–7
   PubMed Web of Science ®Google Scholar
• Allen-Daniels M, Serrano M, Pflugner L, et al. Identification of a gene in Mycoplasma hominis associated with preterm birth and microbial burden in intra-amniotic infection. Am J Obstet Gynecol 2015 Jan 28. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Romero R, Reece E, Duff G, et al. Prenatal diagnosis of Candida albicans chorioamnionitis. Am J Perinatol 1985;2:121–2
   PubMedGoogle Scholar
• Mercer B, Goldenberg R, Das A, et al. What we have learned regarding antibiotic therapy for the reduction of infant morbidity after preterm premature rupture of the membranes. Semin Perinatol 2003;27:217–30
   PubMed Web of Science ®Google Scholar
• Mercer BM. Preterm premature rupture of the membranes. Obstet Gynecol 2003;101:178–93
   PubMed Web of Science ®Google Scholar
• Mercer B, Crouse D, Goldenberg R, et al. The antibiotic treatment of PPROM study: systemic maternal and fetal markers and perinatal outcomes. Am J Obstet Gynecol. 2012;206:145 e141–9
   Google Scholar
• Romero R, Scioscia A, Edberg S, et al. Use of parenteral antibiotic therapy to eradicate bacterial colonization of amniotic fluid in premature rupture of membranes. Obstet Gynecol 1986;67:15S–17S
   PubMed Web of Science ®Google Scholar
• Romero R, Hagay Z, Nores J, et al. Eradication of Ureaplasma urealyticum from the amniotic fluid with transplacental antibiotic treatment. Am J Obstet Gynecol 1992;166:618–20
   PubMed Web of Science ®Google Scholar
• Mazor M, Chaim W, Horowitz S, et al. Successful treatment of preterm labour by eradication of Ureaplasma urealyticum with erythromycin. Arch Gynecol Obstet 1993;253:215–18
   PubMed Web of Science ®Google Scholar
• Mazor M, Chaim W, Meirovitz M, et al. Eradication of viridans streptococci from the amniotic cavity by parenteral antibiotic administration: a case report. J Reprod Med 1995;40:820–2
   PubMed Web of Science ®Google Scholar
• Smorgick N, Frenkel E, Zaidenstein R, et al. Antibiotic treatment of intra-amniotic infection with Ureaplasma urealyticum: a case report and literature review. Fetal Diagn Ther 2007;22:90–3
   PubMed Web of Science ®Google Scholar
• Kim M, Kim G, Romero R, et al. Biovar diversity of Ureaplasma urealyticum in amniotic fluid: distribution, intrauterine inflammatory response and pregnancy outcomes. J Perinat Med 2003;31:146–52
   PubMed Web of Science ®Google Scholar
• Samra Z, Rosenberg S, Dan M. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. J Chemother 2011;23:77–9
   PubMed Web of Science ®Google Scholar
• Park H, Kim S, Huh H, et al. Prevalence and antibiotics susceptibilities of the Ureaplasma species isolated from asymptomatic pregnant women (abstract 163). Am J Obstet Gynecol (Supplement) 2015;212:S97
   Web of Science ®Google Scholar
• Duffy L, Crabb D, Searcey K, et al. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J Antimicrob Chemother 2000;45:29–33
   PubMed Web of Science ®Google Scholar
• Chu S, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992;36:1147–50
   PubMed Web of Science ®Google Scholar
• Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999;37:385–98
   PubMed Web of Science ®Google Scholar
• Kafetzis D, Brater D, Fanourgakis J, et al. Ceftriaxone distribution between maternal blood and fetal blood and tissues at parturition and between blood and milk postpartum. Antimicrob Agents Chemother 1983;23:870–3
   PubMed Web of Science ®Google Scholar
• Hauth JC. The NICHD-MFMU antibiotic treatment of pPROM study: correlation with acute placental inflammation and perinatal mortality. Am J Obstet Gynecol 1997;176:S53
   Google Scholar
• Bendon R, Faye-Petersen O, Pavlova Z, et al. Fetal membrane histology in preterm premature rupture of membranes: comparison to controls, and between antibiotic and placebo treatment. The National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network, Bethesda, MD, USA. Pediatr Dev Pathol 1999;2:552–8
   PubMed Web of Science ®Google Scholar
• Tsai W, Standiford TJ. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr Pharm Des 2004;10:3081–93
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis E, Adamis T, Laoutaris G, et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004;48:93–9
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis E, Adamis T, Sabracos L, et al. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scand J Infect Dis 2005;37:48–54
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis E, Baziaka F, Antonopoulou A, et al. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli. Int J Antimicrob Agents 2005;25:168–72
   PubMed Web of Science ®Google Scholar
• Baziaka F, Giamarellos-Bourboulis E, Raftogiannis M, et al. Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa. J Chemother 2008;20:63–8
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ. Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents 2008;32:S39–43
   PubMed Web of Science ®Google Scholar
• Atmatzidis S, Koutelidakis I, Chatzimavroudis G, et al. Clarithromycin modulates immune responses in experimental peritonitis. Int J Antimicrob Agents 2011;37:347–51
   PubMed Web of Science ®Google Scholar
• Ichiyama T, Nishikawa M, Yoshitomi T, et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001;45:44–7
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Hagiwara K, Honda Y, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002;49:745–55
   PubMed Web of Science ®Google Scholar
• Spyridaki A, Raftogiannis M, Antonopoulou A, et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother 2012;56:3819–25
   PubMed Web of Science ®Google Scholar
• Segel S, Miles A, Clothier B, et al. Duration of antibiotic therapy after preterm premature rupture of fetal membranes. Am J Obstet Gynecol 2003;189:799–802
   PubMed Web of Science ®Google Scholar
• Alvarez J, Williams S, Ganesh V, et al. Duration of antimicrobial prophylaxis for group B streptococcus in patients with preterm premature rupture of membranes who are not in labor. Am J Obstet Gynecol 2007;197:390 e391–4
   Google Scholar
• Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010;7:653–60
   PubMed Web of Science ®Google Scholar
• Dielubanza E, Schaeffer AJ. Urinary tract infections in women. Med Clin North Am 2011;95:27–41
   PubMed Web of Science ®Google Scholar
• Wagenlehner F, Wullt B, Perletti G. Antimicrobials in urogenital infections. Int J Antimicrob Agents 2011;38:3–10
   PubMed Web of Science ®Google Scholar
• Nicolle LE. Urinary tract infection. Crit Care Clin 2013;29:699–715
   PubMed Web of Science ®Google Scholar
• Barber A, Norton J, Spivak A, et al. Urinary tract infections: current and emerging management strategies. Clin Infect Dis 2013;57:719–24
   PubMed Web of Science ®Google Scholar
• Wing DA. Pyelonephritis in pregnancy: treatment options for optimal outcomes. Drugs 2001;61:2087–96
   PubMed Web of Science ®Google Scholar
• Jolley J, Wing DA. Pyelonephritis in pregnancy: an update on treatment options for optimal outcomes. Drugs 2010;70:1643–55
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton T, Naber K, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103–20
   PubMed Web of Science ®Google Scholar
• Jolley J, Kim S, Wing DA. Acute pyelonephritis and associated complications during pregnancy in 2006 in US hospitals. J Matern Fetal Neonatal Med 2012;25:2494–8
   PubMed Web of Science ®Google Scholar
• Eliakim-Raz N, Yahav D, Paul M, et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection – 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2013;68:2183–91
   PubMed Web of Science ®Google Scholar
• Wing D, Fassett M, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol 2014;210:219 e211–16
   Google Scholar
• French L, Smaill FM. Antibiotic regimens for endometritis after delivery. Cochrane Database Syst Rev 2004;4:CD001067
   PubMedGoogle Scholar
• Faro S. Postpartum endometritis. Clin Perinatol 2005;32:803–14
   PubMed Web of Science ®Google Scholar
• Jaiyeoba O. Postoperative infections in obstetrics and gynecology. Clin Obstet Gynecol 2012;55:904–13
   PubMed Web of Science ®Google Scholar
• Lapinsky SE. Obstetric infections. Crit Care Clin 2013;29:509–20
   PubMed Web of Science ®Google Scholar
• Fihn S, Stamm WE. Interpretation and comparison of treatment studies for uncomplicated urinary tract infections in women. Rev Infect Dis 1985;7:468–78
   PubMedGoogle Scholar
• Stray-Pdersen B, Blakstad M, Bergan T. Bacteriuria in the puerperium. Risk factors, screening procedures, and treatment programs. Am J Obstet Gynecol 1990;162:792–7
   PubMed Web of Science ®Google Scholar
• Duffy M. Everything you always wanted to know about graduate nursing education. Imprint. 1994;41:12–15, 17–18
   PubMedGoogle Scholar
• Iravani A, Tice A, McCarty J, et al. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected]. Arch Intern Med 1995;155:485–94
   PubMed Web of Science ®Google Scholar
• Edwards R, Clark P, Sistrom C, et al. Intrapartum antibiotic prophylaxis 1: relative effects of recommended antibiotics on gram-negative pathogens. Obstet Gynecol 2002;100:534–9
   PubMed Web of Science ®Google Scholar
• Bizzarro M, Dembry L, Baltimore R, et al. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics 2008;121:689–96
   PubMed Web of Science ®Google Scholar
• Gregory M, Eichenwald E, Puopolo KM. Seven-year experience with a surveillance program to reduce methicillin-resistant Staphylococcus aureus colonization in a neonatal intensive care unit. Pediatrics 2009;123:e790–6
   PubMed Web of Science ®Google Scholar